A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Name: A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
License: Public Domain

Dana-Farber Cancer Institute · clinicaltrials

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

endometrial cancer

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Record · ID 67861 · SHA-256 e5bfa50054351e7a
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.